Cover Image
Market Research Report
Product code 
1034176

Herpes Zoster Infection Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Published: | Mordor Intelligence Pvt Ltd | 110 Pages | Delivery time: 2-3 business days

Price

Back to Top
Herpes Zoster Infection Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Published: January 17, 2022
Mordor Intelligence Pvt Ltd
Content info: 110 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The herpes zoster infection treatment market is projected to register a CAGR 4.1% during the forecast period.

Herpes zoster infection is caused by the reactivation of the varicella-zoster virus, which occurs in patients having immunosuppressive diseases or cell-mediated immunity declines with age. Coronavirus disease which is caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been linked with T-cell immunological dysfunction. COVID-19 infection could be a cause for herpes zoster reactivation. For instance, as per the study published in PUBMED in 2021 on COVID-19 individuals, varicella-zoster virus reactivation can occur as a result of T cell malfunction, such as lymphopenia and lymphocyte depletion. Patients with COVID-19 are more prone to reactivate herpes zoster due to the tendency of COVID-19 to establish an immunosuppressive state, related to the functional impairment and the concurrent quantitative drop in T lymphocytes, especially CD4+ T cells, CD8+ T cells, and natural killer cells. Additionally, a study on Pubmed central 2021 reported that in some cases, reactivation of the varicella-zoster virus after vaccination for SARS-CoV-2 has been reported during post-marketing surveillance. Therefore, the management of herpes infection has gained more importance during the ongoing COVID-19 outbreak.

The key market drivers for the growth of the herpes zoster infection treatment market include the rising geriatric population coupled with the rising incidence of herpes zoster and growing awareness regarding the use of the varicella vaccine and an increase in immunization programs across the world. According to the Centers for Disease Control and Prevention (CDC) 2020, the incidence of herpes zoster among 60 years and older is about 1 case per 100 U.S. population annually and about 1 to 4% of patients get hospitalized for complications, among whom 30% have compromised immune systems. Because of weak immune systems, elderly people are more susceptible to herpes zoster.

Also, chemotherapy and radiation decrease immunity and increase the risk of herpes zoster in cancer patients. Also, the risk of developing herpes zoster is higher for people who have had chickenpox in the past. Thus, rising prevalence of the cancer and associated disorders as well as increasing elderly population will help the market to grow at a faster pace.

Herpes zoster is diagnosed with a blood test that detects the viral antibodies and is treated with oral, topical, and vaccination medications. Antivirals, analgesics, and NSAIDs are commonly used to treat the symptoms. Vaccines are mostly administered to older adults who are at a higher risk of contracting herpes zoster because of their weakened immune systems.

Additionally, the market is also driven by increasing awareness about the use of varicella vaccinations, an increase in the adoption of varicella vaccines, and active government participation in immunization programmers.

However, the high cost of the vaccine is likely to hinder market growth over the coming years.

Key Market Trends

Acyclovir Antiviral Drug Segment is Expected to Hold Significant Market Share Over the Forecast Period

The acyclovir antiviral drug segment holds a significant market share in the herpes zoster infection treatment market and is anticipated to show a similar trend over the forecast period as it reduces viral shedding and accelerates resolution of symptoms such as reducing pain, develop fast healing, and avoid post-herpetic neuralgia. Hence it is getting attention from major players as different clinical trials are being conducted to understand its role in the management of herpes zoster infection. For instance, in 2018, CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD conducted a clinical trial in collaboration with Peking University People's Hospital to evaluate the safety and efficacy of intravenous acyclovir in herpes zoster patients from China.

As a result of its cost-effectiveness, many companies are engaged in drug development and the use of acyclovir in herpes zoster is predicted to be significant. For instance, in May 2018, Avet Pharmaceuticals Inc. launched generic acyclovir 200mg capsules for the treatment of herpes zoster, genital herpes, and chickenpox. This is likely to have a positive impact on the segment studied.

Moreover, according to the Centers for Disease Control and Prevention (CDC) 2020, there are approximately one million cases of herpes zoster that occur in the United States each year and it affects approximately 1 in 3 people in the United States during their lifetime. Aciclovir is most commonly prescribed for the varicella zoster virus or herpes simplex virus. Thus, easy availability and extensive utilization of acyclovir are the key driving factors in the acyclovir antiviral drug segment.

North America is Expected to Hold a Major Share of the Market in the Forecast Period

The North American region is expected to hold a major market share of the global herpes infection treatment market, due to the high incidence rate of herpes zoster in North America and readily available medications. The presence of major players involved in the commercialization and development of herpes zoster interventions is a primary factor for the growth of this market in this region.

Major companies are focusing on developing and marketing safe and effective vaccines to treat herpes zoster infection by conducting various clinical trials. For instance, in December 2019, GlaxoSmithKline plc started a clinical trial to study long-term immune responses to the Herpes Zoster subunit vaccine along with safety up to 7 years. The study is under Phase 3 of the clinical trial and is expected to be completed by April 2024. Additionally, increased government support for vaccination and awareness programs and funds in this area are likely to propel the market forward throughout the forecast period.

Competitive Landscape

The Global Herpes Zoster Market is moderately fragmented. Some of the companies which are currently dominating the market are GlaxoSmithKline PLC, Merck & Co. Inc., GC Pharma (Green Cross Holdings), Bio-Med Pvt Ltd, Novo Medi Sciences Pvt Ltd, Sanofi, and others. Major players in the market are focused on expanding their business in the developed and fast-growing markets by launching their products to meet the demand for herpes zoster interventions. For instance, in May 2019, GlaxoSmithKline plc announced the approval of Shingrix, a vaccine to prevent herpes zoster by China's National Medical Products Administration (NMPA).

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 72243

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population Coupled with Rising incidence of Herpes Zoster
    • 4.2.2 Growing Awareness Regarding the Use of Varicella Vaccine and Increase in Immunization Programs Across the World
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Vaccine
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Drug Therapy
      • 5.1.1.1 Antivirals
      • 5.1.1.2 Analgesic
      • 5.1.1.3 Nonsteroidal Anti-inflammatory Drugs
      • 5.1.1.4 Others
    • 5.1.2 Vaccination
      • 5.1.2.1 Monovalent Vaccine
      • 5.1.2.2 Combination Vaccine
  • 5.2 End User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Diagnostic Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline PLC
    • 6.1.2 Merck & Co. Inc.
    • 6.1.3 GC Pharma (Green Cross Holdings)
    • 6.1.4 Bio-Med Pvt Ltd
    • 6.1.5 Novo Medi Sciences Pvt Ltd
    • 6.1.6 Sanofi
    • 6.1.7 Takeda Pharmaceutical Company Limited
    • 6.1.8 Mitsubishi Tanabe Pharma Corporation
    • 6.1.9 Novartis AG
    • 6.1.10 Camber Pharmaceuticals, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS